208 related articles for article (PubMed ID: 29039762)
41. Variation in the alkaloids among indo-pacific Leucetta sponges.
Crews P; Clark DP; Tenney K
J Nat Prod; 2003 Feb; 66(2):177-82. PubMed ID: 12608847
[TBL] [Abstract][Full Text] [Related]
42. Meridianins: marine-derived potent kinase inhibitors.
Bharate SB; Yadav RR; Battula S; Vishwakarma RA
Mini Rev Med Chem; 2012 Jun; 12(7):618-31. PubMed ID: 22512550
[TBL] [Abstract][Full Text] [Related]
43. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
[TBL] [Abstract][Full Text] [Related]
44. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
[TBL] [Abstract][Full Text] [Related]
45. Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.
Massey AJ; Benwell K; Burbridge M; Kotschy A; Walmsley DL
J Cell Mol Med; 2021 Nov; 25(22):10650-10662. PubMed ID: 34708541
[TBL] [Abstract][Full Text] [Related]
46. Naamidines H and I, cytotoxic imidazole alkaloids from the Indonesian marine sponge Leucetta chagosensis.
Tsukamoto S; Kawabata T; Kato H; Ohta T; Rotinsulu H; Mangindaan RE; van Soest RW; Ukai K; Kobayashi H; Namikoshi M
J Nat Prod; 2007 Oct; 70(10):1658-60. PubMed ID: 17822294
[TBL] [Abstract][Full Text] [Related]
47. Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential.
Martín Moyano P; Němec V; Paruch K
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066143
[TBL] [Abstract][Full Text] [Related]
48. Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer's Disease Therapeutic Agents.
Llorach-Pares L; Nonell-Canals A; Sanchez-Martinez M; Avila C
Mar Drugs; 2017 Nov; 15(12):. PubMed ID: 29186912
[TBL] [Abstract][Full Text] [Related]
49. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.
Deslandes S; Chassaing S; Delfourne E
Mar Drugs; 2009 Dec; 7(4):754-86. PubMed ID: 20098609
[TBL] [Abstract][Full Text] [Related]
50. Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.
Hui R; El Bakkouri M; Sibley LD
Trends Pharmacol Sci; 2015 Jul; 36(7):452-60. PubMed ID: 26002073
[TBL] [Abstract][Full Text] [Related]
51. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
[TBL] [Abstract][Full Text] [Related]
52. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805
[TBL] [Abstract][Full Text] [Related]
53. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
54. Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition.
Soundararajan M; Roos AK; Savitsky P; Filippakopoulos P; Kettenbach AN; Olsen JV; Gerber SA; Eswaran J; Knapp S; Elkins JM
Structure; 2013 Jun; 21(6):986-96. PubMed ID: 23665168
[TBL] [Abstract][Full Text] [Related]
55. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Abbassi R; Johns TG; Kassiou M; Munoz L
Pharmacol Ther; 2015 Jul; 151():87-98. PubMed ID: 25795597
[TBL] [Abstract][Full Text] [Related]
56. Kinase inhibitors from marine sponges.
Skropeta D; Pastro N; Zivanovic A
Mar Drugs; 2011; 9(10):2131-2154. PubMed ID: 22073013
[TBL] [Abstract][Full Text] [Related]
57. Total syntheses and cytotoxicity of kealiiquinone, 2-deoxy-2-aminokealiiquinone and analogs.
Das J; Bhan A; Mandal SS; Lovely CJ
Bioorg Med Chem Lett; 2013 Nov; 23(22):6183-7. PubMed ID: 24076171
[TBL] [Abstract][Full Text] [Related]
58. Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors.
Rothweiler U; Eriksson J; Stensen W; Leeson F; Engh RA; Svendsen JS
Eur J Med Chem; 2015 Apr; 94():140-8. PubMed ID: 25768698
[TBL] [Abstract][Full Text] [Related]
59. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Smith B; Medda F; Gokhale V; Dunckley T; Hulme C
ACS Chem Neurosci; 2012 Nov; 3(11):857-72. PubMed ID: 23173067
[TBL] [Abstract][Full Text] [Related]
60. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
